35th Annual CFS®

Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is eligible for ACPE credit; see final CPE activity announcement for specific details.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

35th Annual CFS®

35th Annual CFS®

Wednesday, November 8, 2017 – Friday, November 10, 2017
New York Marriott Marquis
1535 Broadway

New York, NY 10036
(800) 843-4898 | Book Online


Advances in all aspects of cancer care—including diagnostic, therapeutic, and supportive strategies—form the foundation for recent changes in the management of solid and hematologic malignancies. For many tumor types, integration into practice of novel testing approaches, systemic therapies, molecular targeted therapies, immunotherapies, and multimodal strategies, continue to improve patient outcomes in multiple lines of care. Each year, the CFS®, brings together more than 2,000 oncologists, hematologists, radiation oncologists, immunologists, pharmacists, oncology nurses, nurse practitioners, physician assistants, and case managers, with the aim of promoting the delivery of state-of-the-art cancer care for the most challenging clinical scenarios. At the 34th Annual CFS®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics. This exciting 3-day program will offer oncology practitioners an unparalleled opportunity to learn how innovative approaches fit into evolving treatment paradigms to optimize care and outcomes for their patients with cancer.

Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  1. Determine the most appropriate testing strategies to stratify risk and inform clinical decision-making in the management of cancer
  2. Describe important clinical trial results that inform treatment practices and are altering care paradigms for patients with hematologic malignancies and solid tumors
  3. Identify immunotherapeutic, chemotherapeutic, and targeted approaches demonstrated by recent evidence to optimize clinical outcomes
  4. Delineate methods multidisciplinary teams can proactively apply to prevent and mitigate the impact of treatment-related toxicities findings in the context of evolving treatment pathways to improve care for patients with cancer
  5. Assess practice-changing evidence and apply these findings in the context of evolving treatment paradigms to optimize the care of patients with cancer

2017 Hot Topics

  • Immunotherapies and Their Latest Applications in Cancer, Including Combinations
  • Harnessing the Latest Technologies, Biomarkers, and Tests to Optimize Clinical Decision Making
  • Microsatellite Instability‒Guided Care Across Multiple Tumor Types
  • How to Maximize Outcomes in Multiple Myeloma
  • Factoring MRD Into Treatment Plans for Patients With Hematologic Malignancies
  • Tackling Clinical Challenges in the Management of Myeloproliferative Neoplasms
  • Practice-Changing Paradigms in Acute Leukemias
  • Providing State-of-the-Art Care for Older Patients With Hematologic Malignancies
  • Coming Soon to Your Clinic: Evolving Strategies for Hepatocellular Carcinoma, Pancreatic Cancer, and Gastric Cancer
  • Options and Considerations for Metastatic Colorectal Cancer in the Frontline and Beyond Progression
  • Progress in Soft-Tissue Sarcoma and Non‒Soft-Tissue Sarcoma
  • Ovarian Cancer: PARP Inhibition, Maintenance Strategies, Immunotherapy, Angiogenesis Targeting, and Clinical Trial Designs
  • Novel Therapeutic Approaches in Breast Cancer Treatment: Immunotherapy and Combinations
  • Treatment Planning for Early, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Considerations
  • Individualized Care for Patients With Advanced Triple-Negative Breast Cancer
  • Precision Care for Patients With Non-Small Cell and Small Cell Lung Cancer
  • Bladder Cancer: More Options, More Clinical Considerations
  • New Horizons in Prostate Cancer: Expert Sequencing, Targeting DNA Repair Deficiency, and Immunotherapy
  • Updates in Glioblastoma: Technologies, Targeted Therapy, and Immunotherapy
  • Optimizing Your Patients’ Quality of Life: Focus on CINV, Sexuality, and Palliation
  • Advances in Melanoma and Nonmelanoma Carcinomas
  • Cancer-Associated Cardiomyopathy: Web-Based Diagnostic and Management Technologies
  • Moon Shots Program™ Update

And much more!

Program Co-Chairs

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/ Oncology
Co-Director, Comprehensive Breast Cancer Center Associate
Director, Clinical Investigation
University of Pittsburgh
Pittsburgh, PA

Benjamin Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

William Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, NY

Calendar of Events
Filter By